The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma.

Abstract

BACKGROUND:

Lung cancer claims more lives than any other cancer worldwide. Lung adenocarcinoma (LUAD) accounts for approximately 40% of all lung cancers. Members of the Transducin-like Enhancer of split (TLE) protein family repress transcription through multiple mechanisms; however, their prognostic value in LUAD is still unclear.

METHODS:

A dataset from The Cancer Genome Atlas was used to analyze the relationship between the expression of TLE family members and outcomes of LUAD. The expression of TLE family members in 59 normal and 513 tumor samples in the TCGA dataset was selected. For paired analysis, 57 normal and 57 tumor paired tissues were selected. Gene Ontology (GO) term and Reactome pathway enrichment analyses of the TLE family members were performed. Progression-free survival (PFS) and overall survival (OS) served as endpoints in this study. All statistical analyses were performed with R 3.6.0.

RESULTS:

The expression levels of TLE family proteins differed between 59 normal and 513 tumor samples. High TLE1 and low TLE2 levels were associated with poor progression-free and OS (all P<0.050). Multivariate analysis demonstrated that high TLE1 expression and low TLE2 expression were independent risk factors for a poor outcome in LUAD. Moreover, the combined expression of these two proteins was a good tool for prognostication.

CONCLUSIONS:

High TLE1 expression and low TLE2 are independent adverse prognostic factors in LUAD and can serve as prognostic biomarkers.

• Authors: Qianli Ma, Fei Xiao, Yang Hao, Zhiyi Song, Jin Zhang, Chaozeng Si, Chaoyang Liang, Deruo Liu
• Journal: Translational lung cancer research (Transl Lung Cancer Res) Vol. 10 Issue 7 Pg. 3251-3263 (Jul 2021) ISSN: 2218-6751 [Print] China
• PMID: 34430362 (Publication Type: Journal Article)
• Copyright: 2021 Translational Lung Cancer Research. All rights reserved.